Adding colchicine to tocilizumab in hospitalized patients with severe COVID-19 pneumonia: An open-label randomized controlled trial
<h3>Introduction:</h3><p dir="ltr">Colchicine acts upstream in the cytokines cascade by inhibiting the nod-like receptor protein 3 (NLRP3) inflammasome while interleukin 6 (IL-6) receptor antagonists, such as tocilizumab, block the end result of the cytokines cascade. Hen...
محفوظ في:
مواد مشابهة
-
The efficacy of colchicine in the management of coronavirus disease 2019
حسب: Mohamed Nabil Elshafei (9960500)
منشور في: (2020) -
The effect of colchicine on myocardial infarction: An updated systematic review and meta-analysis of randomized controlled trials
حسب: Ayesha, Younas
منشور في: (2024) -
Tocilizumab‐induced cytomegalovirus colitis in a patient with COVID‐19
حسب: Mohamad Y. Khatib (11659459)
منشور في: (2020) -
Does colchicine reduce mortality in patients with COVID-19 clinical syndrome? An umbrella review of published meta-analyses
حسب: Mohammed I., Danjuma
منشور في: (2023) -
The effect of colchicine on myocardial infarction: An updated systematic review and meta-analysis of randomized controlled trials
حسب: Ayesha Younas (7114868)
منشور في: (2025)